OGN
Organon & Co.
Key Financials
Net Income
$187.0M
↓ 78.4%
Gross Profit
$3.3B
↓ 10.8%
Revenue
$6.2B
↓ 2.9%
Total Assets
$12.9B
↓ 1.8%
Total Liabilities
$12.1B
↓ 4.1%
Shareholders' Equity
$752.0M
↑ 59.3%
EPS (Diluted)
$0.72
↓ 78.4%
Long-term Debt
$8.6B
↓ 2.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEFM14A | 6/17/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | OGN |
| Company Name | Organon & Co. |
| CIK | 1821825 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 551-430-6000 |